Emergence of a novel drug resistant H7N9 influenza virus: Evidence based clinical potential of a natural IFN-α for infection control and treatment

Expert Review of Anti-Infective Therapy

Volumn 12, Issue 2, 2014, Pages 165-169

  Liu, Qinfang ^a   Ma, Jingjiao ^a   Strayer, David R ^b   Mitchell, William M ^c   Carter, William A ^b   Ma, Wenjun ^a   Richt, Juergen A ^a  

^a KANSAS STATE UNIVERSITY   (United States)

^b HEMISPHERX BIOPHARMA INC   (United States)

^c VANDERBILT UNIVERSITY   (United States)

Author keywords

Alferon N; antiviral drug; H7N9; influenza; neuraminidase inhibitors; oseltamivir resistance; tamiflu

Indexed keywords

ALPHA INTERFERON; ALPHAN3 INTERFERON; AMANTADINE; BETA INTERFERON; FAVIPIRAVIR; OSELTAMIVIR; PERAMIVIR; PROTEIN INHIBITOR; PROTEIN M2; RIMANTADINE; SIALIDASE INHIBITOR; VIRUS SIALIDASE; ZANAMIVIR;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CHINA; DRUG APPROVAL; HUMAN; IN VITRO STUDY; INFECTION CONTROL; INFLUENZA A; INFLUENZA A (H7N9); INFLUENZA VIRUS A H7N9; MORTALITY; PATHOGENESIS; VIRUS IMMUNITY; VIRUS ISOLATION; VIRUS REPLICATION; WILD TYPE;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; DOGS; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; HUMANS; IMMUNOLOGIC FACTORS; INFLUENZA A VIRUS, H7N9 SUBTYPE; INFLUENZA, HUMAN; INTERFERON-ALPHA; MADIN DARBY CANINE KIDNEY CELLS; MEMBRANE TRANSPORT MODULATORS; MUTATION; NEURAMINIDASE; OSELTAMIVIR; VIRAL MATRIX PROTEINS; VIRUS REPLICATION;

EID: 84893098314     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2014.870885     Document Type: Article

References (33)

1. Gaö R, Caö B, Hu Y, et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 2013; 368(20):1888-97
2. Mei Z, Lu S, Wu X, et al. Avian influenza A(H7N9) virus infections, Shanghai, China. Emerg Infect Dis 2013;19(7):1179-81
3. Salathe M, Freifeld CC, Mekaru SR, et al. Influenza A (H7N9) and the importance of digital epidemiology. N Engl J Med 2013; 369(5):401-4
4. Li Q, Zhou L, Zhou M, et al. Preliminary report: epidemiology of the Avian Influenza A (H7N9) outbreak in China. N Engl J Med 2013; Epub ahead of print
5. Hu Y, Lu S, Song Z, et al. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet 2013;381(9885):2273-9
6. Tö KK, Chan JF, Chen H, et al. The emergence of influenza A H7N9 in human beings 16 years after influenza A H5N1: a tale of twö cities. Lancet Infect Dis 2013; 13(9):809-21
7. Zhang Q, Shi J, Deng G, et al. H7N9 influenza viruses are transmissible in ferrets by respiratory droplet. Science 2013; 341(6144):410-14
8. Zhou J, Wang D, Gaö R, et al. Biological features of novel avian influenza A (H7N9) virus. Nature 2013;499(7459):500-3
9. Watanabe T, Kisö M, Fukuyama S, et al. Characterization of H7N9 influenza A viruses isolated from humans. Nature 2013;501(7468):551-5
10. Lam TT, Wang J, Shen Y, et al. The genesis and source of the H7N9 influenza viruses causing human infections in China. Nature 2013;502(7470):241-4
11. Hatta M, Gaö P, Halfmann P, Kawaoka Y. Molecular basis for high virulence of Hong Kong H5N1 influenza A viruses. Science 2001;293(5536):1840-2
12. Belser JA, Gustin KM, Pearce MB, et al. Pathogenesis and transmission of avian influenza A (H7N9) virus in ferrets and mice. Nature 2013;501(7468):556-9
13. Richard M, Schrauwen EJ, de Graaf M, et al. Limited airborne transmission of H7N9 influenza A virus between ferrets. Nature 2013;501(7468):560-3
14. Zhu H, Wang D, Kelvin DJ, et al. Infectivity, transmission, and pathology of human-isolated H7N9 influenza virus in ferrets and pigs. Science 2013;341(6142): 183-6
15. Ma W, Kahn RE, Richt JA. The pig as a mixing vessel for influenza viruses: human and veterinary implications. J Mol Genet Med 2008;3(1):158-66
16. Schmidt AC. Antiviral therapy for influenza: a clinical and economic comparative review. Drugs 2004;64(18):2031-46
17. Beigel J, Bray M. Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res 2008;78(1):91-102
18. Grambas S, Bennett MS, Hay AJ. Influence of amantadine resistance mutations on the pH regulatory function of the M2 protein of influenza A viruses. Virology 1992; 191(2):541-9
19. Hay AJ, Hayden FG. Oseltamivir resistance during treatment of H7N9 infection. Lancet 2013;381(9885):2230-2
20. Yen HL, Herlocher LM, Hoffmann E, et al. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob Agents Chemother 2005;49(10):4075-84
21. Yen HL, McKimm-Breschkin JL, Choy KT, et al. Resistance. tö neuraminidase inhibitors conferred by an R292K mutation in a human influenza virus H7N9 isolate can be masked by a mixed R/K viral population. MBiö 2013;4(4):e00396-13
22. Rossignol JF, La Frazia S, Chiappa L, et al. Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level. J Biol Chem 2009;284(43):29798-808
23. Furuta Y, Gowen BB, Takahashi K, et al. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 2013;100(2):446-54
24. Zhirnov OP, Klenk HD, Wright PF. Aprotinin and similar protease inhibitors as drugs against influenza. Antiviral Res 2011; 92(1):27-36
25. Antonelli G. Biological basis for a proper clinical application of alpha interferons. New Microbiol 2008;31(3):305-18
26. Haasbach E, Droebner K, Vogel AB, Planz O. Low-dose interferon Type I treatment is effective against H5N1 and swine-origin H1N1 influenza A viruses in vitrö and in vivo. J Interferon Cytokine Res 2011;31(6):515-25
27. Osterlund P, Pirhonen J, Ikonen N, et al. Pandemic H1N1 2009 influenza A virus induces weak cytokine responses in human macrophages and dendritic cells and is highly sensitive tö the antiviral actions of interferons. J Virol 2010;84(3):1414-22
28. Silverman RH. Viral encounters with 2',5'-oligoadenylate synthetase and RNase L during the interferon antiviral response. J Virol 2007;81(23):12720-9
29. Garcia MA, Gil J, Ventosö I, et al. Impact of protein kinase PKR in cell biology: from antiviral tö antiproliferative action. Microbiol Mol Biol Rev 2006;70(4): 1032-60
30. Haller O, Staeheli P, Kochs G. Interferoninduced Mx proteins in antiviral host defense. Biochimie 2007;89(6-7):812-18
31. Tan EL, Ooi EE, Lin CY, et al. Inhibition of SARS coronavirus infection in vitrö with clinically approved antiviral drugs. Emerg Infect Dis 2004;10(4):581-6
32. Strayer DR, Carter WA. Recombinant and natural human interferons: analysis of the incidence and clinical impact of neutralizing antibodies. J Interferon Cytokine Res 2004; 32(3):95-102
33. Liu Q, Qiaö C, Marjuki H, et al. Combination of PB2 271A and SR polymorphism at positions 590/591 is critical for viral replication and virulence of swine influenza virus in cultured cells and in vivo. J Virol 2012;86(2):1233-7